Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
:TAK
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of $45.55B. The enterprise value is $73.10B.
Market Cap$45.55B
Enterprise Value$73.10B
Share Statistics
Takeda Pharmaceutical Company has 3,181,971,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,181,971,700
Owned by Insiders―
Owned by Institutions0.78%
Financial Efficiency
Takeda Pharmaceutical Company’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.72%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.72%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee92.97M
Profits Per Employee2.19M
Employee Count49,281
Asset Turnover0.32
Inventory Turnover1.30
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Company is 169.5. Takeda Pharmaceutical Company’s PEG ratio is -2.57.
PE Ratio169.5
PS Ratio1.56
PB Ratio1.03
Price to Fair Value1.03
Price to FCF8.36
Price to Operating Cash Flow6.79
PEG Ratio-2.57
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of 4.58T and earned 107.93B in profits. Earnings per share was 34.17.
Revenue4.58T
Gross Profit3.00T
Operating Income342.59B
Pretax Income175.08B
Net Income107.93B
EBITDA1.21T
Earnings Per Share (EPS)34.17
Cash Flow
In the last 12 months, operating cash flow was 1.20T and capital expenditures -221.77B, giving a free cash flow of 977.79B billion.
Operating Cash Flow1.20T
Free Cash Flow977.79B
Free Cash Flow per Share307.29
Dividends & Yields
Takeda Pharmaceutical Company pays an annual dividend of $0.321, resulting in a dividend yield of 4.22%
Dividend Per Share$0.321
Dividend Yield4.22%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.02
52-Week Price Change6.80%
50-Day Moving Average14.31
200-Day Moving Average14.54
Relative Strength Index (RSI)54.13
Average Volume (3m)2.99M
Important Dates
Takeda Pharmaceutical Company upcoming earnings date is Jan 29, 2026, Before Open (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateJan 29, 2026
Ex-Dividend DateSep 30, 2025
Financial Position
Takeda Pharmaceutical Company as a current ratio of 1.01, with Debt / Equity ratio of 65.63%
Current Ratio1.01
Quick Ratio0.52
Debt to Market Cap0.63
Net Debt to EBITDA3.87
Interest Coverage Ratio2.49
Taxes
In the past 12 months, Takeda Pharmaceutical Company has paid 66.94B in taxes.
Income Tax66.94B
Effective Tax Rate0.38
Enterprise Valuation
Takeda Pharmaceutical Company EV to EBITDA ratio is 9.78, with an EV/FCF ratio of 13.83.
EV to Sales2.58
EV to EBITDA9.78
EV to Free Cash Flow13.83
EV to Operating Cash Flow11.20
Balance Sheet
Takeda Pharmaceutical Company has $739.68B in cash and marketable securities with $4.65T in debt, giving a net cash position of -$3.91T billion.
Cash & Marketable Securities$739.68B
Total Debt$4.65T
Net Cash-$3.91T
Net Cash Per Share-$1.23K
Tangible Book Value Per Share-$629.15
Margins
Gross margin is 52.77%, with operating margin of 7.48%, and net profit margin of 2.36%.
Gross Margin52.77%
Operating Margin7.48%
Pretax Margin3.82%
Net Profit Margin2.36%
EBITDA Margin26.42%
EBIT Margin9.80%
Analyst Forecast
The average price target for Takeda Pharmaceutical Company is $18.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.00
Price Target Upside27.84% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-1.98%
EPS Growth Forecast-86.20%